SunTrust Robinson analyst Peter Lawson reiterated a Buy rating on Affimed (NASDAQ: AFMD) on August 28 and set a price target of $7. The company’s shares closed yesterday at $5.30.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of 13.8% and a 51.2% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals Inc, CytomX Therapeutics Inc, and Mirati Therapeutics.
Currently, the analyst consensus on Affimed is a Strong Buy with an average price target of $5.50, representing a 3.8% upside. In a report issued on August 28, Jefferies also upgraded the stock to Buy with a $4 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.35 and a one-year low of $1.15. Currently, Affimed has an average volume of 1.47M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Affimed NV is a clinical stage biopharmaceutical company, which engages in discovering and developing highly targeted cancer immunotherapies. The company has three proprietary platform technologies which includes: NK-cell TandAbs, T-cell TandAbs and Trispecific Abs. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Read More on AFMD:
